Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic

Ichiko Kinjyo1, Ksenia Matlawska-Wasowska2,3, Xiaoru Chen4

  • 1Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.